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AllerGen NCE Inc., the Allergy, Genes and Environment
Network, is a national, multi-disciplinary, multi-sectoral
network for research and discovery, knowledge transla-
tion and capacity building. AllerGen is dedicated to
improving the quality of life for allergy asthma and
related immune disease sufferers by supporting research
that leads to new diagnostic tests, better medications,
more effective public policies and an increase in the
number of medical professionals researching and practi-
cing in this area. The Networks of Centres of Excellence
(NCE) program, of which AllerGen is a part, is a strategic
initiative aligned with Canada’s Science and Technology
strategy. The NCE program aims to close the ‘develop-
ment-to-delivery’ gap, and accelerate the rate at which
research results contribute to new, evidence-based, cost-
effective policies, products and services that generate
social and economic benefits for Canadians.
The burden of allergy, asthma and related immune
disease is significant and growing world-wide, and while
the underlying causes of these diseases are actively
being studied, the origins of these diseases are still not
well understood. According to the results of the Interna-
tional Study of Asthma and Allergies in Childhood
(ISAAC) Study, Phase III (2003) results, 47% of Cana-
dian children have suffered from allergic rhinitis; 39%
have experienced wheezing; 22.4% have been diagnosed
with asthma; and, 19% have experienced atopic eczema
[1]. According to Health Canada, non-food allergies are
now the most common chronic condition in Canadians
12 years of age and older [2].
The economic impact of these diseases in Canada is in
excess of $15 billion annually, when one includes the
cost of ambulatory care, in-patient stays, emergency
department visits, physician and facility payments,
prescribed medications and productivity losses at school,
work and at home as a direct result of these diseases
[3]. This annual cost is comparable to the economic
impact of arthritis and other chronic conditions. Ontario
data show that 14% of all asthma-related emergency
department visits occur in children between birth and
4 years of age, and that 21% of asthma prevalent cases
were children and adolescents up to 19 years of age [4].
However, hospital admissions for asthma have decreased
for both children and adults since 1996, and asthma as
a cause of death is relatively uncommon and decreasing
among all age groups in the developed world.
Globally, asthma is more prevalent among the devel-
oped countries and in major city centres [5]. Among the
countries with somewhat lower prevalence rates, such as
India and China, which represent 37% of the global
population, recent research suggests that as these coun-
tries industrialize, allergy, asthma and related immune
disease prevalence rates are rising rapidly, mirroring the
experience of more developed countries.
Given the Canadian Institutes of Health Research’s stra-
tegic vision to position Canada as a world leader in the
creation and use of knowledge derived from health
research that benefits Canadians and the global commu-
nity, Canadian researchers and their international partners
have a significant opportunity to work in collaborative
networks to accelerate the translation of research into
practice, and knowledge to action, to improve allergic dis-
ease and asthma awareness, education, management and
control.
A recent analysis by Teresa To, from The Hospital
for Sick Children [6], reveals that for Ontarians, the
lifetime risk of developing chronic asthma is 1 in 3 -
the same as the risk of developing cancer and diabetes.
However, unlike cancer and diabetes, the substantial
lifetime risk of asthma begins at an early stage in life
and persists throughout the life span, triggering
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and other economic costs.
Building upon the work done in 2004 by a team led by
Rejean Landry, AllerGen developed a publicly available KT
planning tool called Knowledge Translation Planning
Tools for Allergic Disease Researchers. This tool provides a
guide for researchers, their stakeholders and partners to
collaboratively develop translational strategies and tactics
that will help accelerate the rate of dissemination, uptake
and application of allergy, asthma and related immune dis-
ease research to improve the quality of life for patients,
facilitate optimal care by health providers and reduce the
economic drag resulting from the burden of these diseases
[7]. Working with national and international partners,
such as the Karolinska Institute in Sweden, AllerGen is
committed to facilitating efforts to improve allergic disease
and asthma management and control, discover the root
causes of these diseases and accelerate the application of
research findings and KT activities for social and eco-
nomic benefits nationally and globally.
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